Orforglipron is new, so it helps to know exactly what has and hasn't been approved before you speak to a doctor.
✓ 2023 — Phase 2 results published. Early trials showed weight loss that increased with the dose over 36 weeks, which led to large phase 3 studies. (4)
✓ 2025 — Phase 3 ATTAIN trials reported. Two 72-week trials tested orforglipron in adults with obesity or overweight, one without diabetes and one with type 2 diabetes. (1) (2)
✓ April 2026 — Approved overseas for weight management. US regulators approved orforglipron for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. Approvals in the United Kingdom, the United Arab Emirates, Saudi Arabia and China followed later in 2026. (3)
▸ Singapore — Not yet registered. At the time of writing (November 2026), orforglipron is not registered with HSA, so doctors here cannot prescribe it. Please avoid overseas or online sellers: unregistered weight loss products may be fake or unsafe. (5) (6)